Gyawali B - Search Results

1

Lung Cancer Survival Gains: Contributions of Academia and Industry.

Gyawali B, Bouche G, Pantziarka P, Kesselheim AS, Sarpatwari A. Gyawali B, et al. J Law Med Ethics. 2019 Sep;47(3):465-467. doi: 10.1177/1073110519876182. J Law Med Ethics. 2019. PMID: 31560624 No abstract available.

2

Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.

Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R, Traversa G, Perrone F, Martini N, Gyawali B, Addis A. Trotta F, et al. Among authors: gyawali b. BMJ Open. 2019 Dec 10;9(12):e033728. doi: 10.1136/bmjopen-2019-033728. BMJ Open. 2019. PMID: 31826897 Free PMC article.

3

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.

Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Gyawali B, et al. JAMA Netw Open. 2019 Aug 2;2(8):e199570. doi: 10.1001/jamanetworkopen.2019.9570. JAMA Netw Open. 2019. PMID: 31469391 Free PMC article.

4

Challenges and Opportunities for Biomarker Validation.

Hey SP, D'Andrea E, Jung EH, Tessema F, Luo J, Gyawali B, Kesselheim AS. Hey SP, et al. Among authors: gyawali b. J Law Med Ethics. 2019 Sep;47(3):357-361. doi: 10.1177/1073110519876162. J Law Med Ethics. 2019. PMID: 31560620

5

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.

Gyawali B, Hey SP, Kesselheim AS. Gyawali B, et al. EClinicalMedicine. 2020 Apr 13;21:100332. doi: 10.1016/j.eclinm.2020.100332. eCollection 2020 Apr. EClinicalMedicine. 2020. PMID: 32382717 Free PMC article.

6

Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007-2016.

Hwang TJ, Kesselheim AS, Gyawali B. Hwang TJ, et al. Among authors: gyawali b. JNCI Cancer Spectr. 2018 Jun 1;2(2):pky016. doi: 10.1093/jncics/pky016. eCollection 2018 Apr. JNCI Cancer Spectr. 2018. PMID: 31360849 Free PMC article.

7

A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises.

Hey SP, Gyawali B, D'Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. Hey SP, et al. Among authors: gyawali b. J Natl Cancer Inst. 2020 Apr 1;112(4):335-342. doi: 10.1093/jnci/djz211. J Natl Cancer Inst. 2020. PMID: 31651981 Free PMC article.

8

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Naci H, Davis C, Savović J, Higgins JPT, Sterne JAC, Gyawali B, Romo-Sandoval X, Handley N, Booth CM. Naci H, et al. Among authors: gyawali b. BMJ. 2019 Sep 18;366:l5221. doi: 10.1136/bmj.l5221. BMJ. 2019. PMID: 31533922 Free PMC article.

9

Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials.

Effing SMA, Gyawali B. Effing SMA, et al. Among authors: gyawali b. EClinicalMedicine. 2020 Jul 15;25:100458. doi: 10.1016/j.eclinm.2020.100458. eCollection 2020 Aug. EClinicalMedicine. 2020. PMID: 32954236 Free PMC article.

10

Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action.

Bhanvadia SK, Psutka SP, Burg ML, de Wite R, Dhillon HM, Gyawali B, Morgans AK, Goldstein DA, Smith AB, Sun M, Penson DF. Bhanvadia SK, et al. Among authors: gyawali b. Eur Urol Oncol. 2021 Apr 2:S2588-9311(21)00041-9. doi: 10.1016/j.euo.2021.02.007. Online ahead of print. Eur Urol Oncol. 2021. PMID: 33820747 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results